News
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
Uncertainty now dominates the COVID vaccine outlook after official recommendations were stripped for a variety of groups.
Zacks Investment Research on MSN6d
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowNovavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
The Centers for Disease Control and Prevention says children without underlying health conditions "may receive" a COVID-19 ...
User Agreement; Privacy Policy; Ad Choices; Site Map © 2025 American City Business Journals. All rights reserved. Use of ...
The FDA finally approved Novavax's Covid-19 vaccine, but placed restrictions on it that its two competitors in the U.S. do ...
Novavax had expected full approval for broader use by April 1, after the FDA reviewed data from a 30,000-person clinical ...
Shares of Novavax Inc. NVAX slid 6.23% to $6.92 Wednesday, on what proved to be an all-around grim trading session for the ...
Zacks Investment Research on MSN6d
Here's Why Novavax (NVAX) is a Strong Momentum StockTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback